A Phase I/II Study of Docetaxel as a Radiosensitizer for Locally Advanced Cervical Cancer (GIA 13026).

Trial Profile

A Phase I/II Study of Docetaxel as a Radiosensitizer for Locally Advanced Cervical Cancer (GIA 13026).

Withdrawn prior to enrolment
Phase of Trial: Phase I/II

Latest Information Update: 20 Dec 2016

At a glance

  • Drugs Docetaxel (Primary)
  • Indications Cervical cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 09 Mar 2012 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 19 Jan 2010 Status changed from suspended to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top